Table 6.
Bleeding, platelet transfusion, and adverse events.
| Event | Total (N = 73) | Treatment group for thrombocytopenia |
|
|---|---|---|---|
| Hetrombopag (n = 28) | Hetrombopag-rhTPO/rhIL-11 (n = 45) | ||
| Bleeding | |||
| Grade 1 | 0 | 0 | 0 |
| Grade 2 | 5 (6.8) | 1 (3.6) | 4 (8.9) |
| Platelet transfusion | 12 (16.4) | 4 (14.3) | 8 (17.8) |
| Adverse events | |||
| Fever | 4 (5.5) | 2 (7.1) | 2 (4.5) |
| Fatigue | 11 (15.1) | 4 (14.3) | 7 (15.6) |
| Decreased appetite | 8 (11.0) | 3 (10.7) | 5 (11.1) |
| Peripheral edema | 2 (2.7) | 0 | 2 (4.4) |
| Thromboembolic events | 2 (2.7) | 0 | 2 (4.4) |
rhIL, recombinant human interleukin; rhTPO, recombinant human thrombopoietin.